Prescription of twice-weekly hemodialysis in the USA

American Journal of Nephrology

Volumn 19, Issue 6, 1999, Pages 625-633

  Hanson, Julie A ^a   Hulbert Shearon, Tempie E ^a   Ojo, Akinlolu O ^a   Port, Friedrich K ^a,d   Wolfe, Robert A ^a   Agodoa, Lawrence Y C ^c   Daugirdas, John T ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Dialysis dose; End stage renal disease (ESRD); ESRD survival; Hemodialysis schedule

Indexed keywords

CREATININE; SERUM ALBUMIN;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CAUCASIAN; CREATININE BLOOD LEVEL; DOSE KIDNEY FUNCTION RELATION; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; SURVIVAL;

EID: 0032706140     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000013533     Document Type: Article

References (25)

1. United States Renal Data System: USRDS 1999 Annual Data Report. Bethesda, MD, National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, 1999.
2. Parker T: Hemodialysis adequacy; in Henrich WL (ed): Principles and Practice of Dialysis. Baltimore, MD, Williams & Wilkins, 1994, pp 63-75.
3. Sehgal AR, Snow RJ, Singer ME, Amini SB, DeOreo PB, Silver MR, Cebul RD: Barriers to adequate delivery of hemodialysis. Am J Kidney 1998;31:593-601.
4. Held PJ, Brunner F, Odaka M, Garcia JR, Port FK, Gaylin DS: Five-year survival for end-stage renal disease patients in the United States, Europe, and Japan. 1982-1987. Am J Kidney Dis 1990;15:451-457.
5. Owen WF II, Lew NL, Liu Y, Lowrie EG, Lazarus JM: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993;329:1001-1006.
6. McClellan WM, Soucie JM, Krisher J, Caruana R, Haley W, Farmer C: Improving the care of patients treated with hemodialysis: A report from the Health Care Financing Administration's ESRD Core Indicators Project. Am J Kidney Dis 1998;31:584-592.
7. Port FK: Morbidity and mortality in dialysis patients. Kidney Int 1994;46:1728-1737.
8. United States Renal Data System: USRDS 1997 Annual Data Report. Bethesda, MD, National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, 1997.
9. Walser M, Drew HH, Guldan JL: Prediction of glomerular filtration rate from serum creatinine concentration in advanced chronic renal failure. Kidney Int 1993;44:1145-1148.
10. Daugirdas JT: Second generation logarithmic estimates of single pool variable volume of Kt/ V: An analysis of error. J Am Soc Nephrol 1993;4:1205-1213.
11. Institute of Medicine: Kidney Failure and the Federal Government. Washington, DC, National Academy Press, 1991, pp 158-163.
12. ANZDATA Registry: Frequency and hours of dialysis; in Disney APS (ed): Australia and New Zealand Dialysis and Transplant Registry, The Twentieth Report, 1997, pp 89.
13. NKF-DOQI: Clinical Practice Guidelines for Hemodialysis Adequacy. Am J Kidney Dis 1997;30(suppl 1):S17-S21.
14. Daugirdas JT, Ing TS: Chronic hemodialysis prescription: A urea kinetic approach; in Handbook of Dialysis, Chapter 6. Boston, Little, Brown, 1994, pp 99-103.
15. Port FK, Orzol SM, Held PJ, Wolfe RA: Trends in treatment and survival for hemodialysis patients in the United States. Am J Kidney Dis 1998;32(suppl 4):S34-S38.
16. Japanese Society for Dialysis Therapy: An overview of regular dialysis treatment in Japan as of December 31, 1997. Tokyo, Bunkyo-ku, 1997, p 226.
17. Lysaght M, Vonesh E, Gotch F, Ibels L, Keen M, Lindholm B, Nolph K, Pollock C, Prowant B, Farrell P: The influence of dialysis treatment modality on the decline in remaining renal function. ASAIO Transactions 1991;37:598-604.
18. Moist LM, Port FK, Orzol SM, Young E, Wolfe RA, Bloembergen WE: Predictors of loss of residual renal function among new dialysis patients. Am Soc Nephrol 1999, in press.
19. Held PJ, Blagg CR, Liska DW, Port FK, Hakim R, Levin N: The dose of hemodialysis according to dialysis prescription in Europe and the United States. Kidney Int 1992;42 (suppl 38):S16-S21.
20. Held PJ, Port FK, Wolfe RA, Stannard DC, Daugirdas JT, Bloembergen WE, Greer JW, Hakim RM: The dose of hemodialysis and patient mortality. Kidney Int 1996;50:550-556.
21. Port FK: Treatment time for hemodialysis. What should it be? ASAIO J 1997;43:225-227.
22. Charra B: Dialysis time: What should it be? ASAIO J 1997;43:228-229.
23. Kjellstrand CM: Duration and adequacy of dialysis. Overview: The science is easy, the ethic is difficult. ASAIO J 1997;43:220-224.
24. Held PJ, Levin NW, Bovbjerg RR, Pauly MV, Diamond LH: Mortality and duration of hemodialysis treatment. JAMA 1991;265:871-875.
25. Van Stone JC: The effect of dialyzer membrane and etiology of kidney disease on the preservation of residual renal function in chronic hemodialysis patients. ASAIO J 1995;41:M713-M716.